Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$9.12
$9.20
$4.30
$13.66
$458.93M1.531.18 million shsN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$19.75
+2.9%
$17.52
$2.03
$14.36
$185.61M1.1150,104 shs240,714 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.35
+7.4%
$3.58
$2.28
$6.71
$513.76M1.71.16 million shs494,558 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$3.17
-1.7%
$2.86
$2.50
$8.32
$98.17M0.9869,235 shs28,527 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00%0.00%0.00%0.00%0.00%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
+28.36%+11.57%+12.82%+83.46%-50.10%
Organogenesis stock logo
ORGO
Organogenesis
+7.14%+14.41%+52.26%-0.49%+52.26%
XBiotech Inc. stock logo
XBIT
XBiotech
+1.58%+21.05%+12.59%+9.15%-43.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
4.0982 of 5 stars
3.03.00.04.30.04.20.6
XBiotech Inc. stock logo
XBIT
XBiotech
0.5104 of 5 stars
0.00.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0037.93% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M5.36N/AN/A($0.34) per share-26.82
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.14$0.22 per share19.41$2.09 per share2.08
XBiotech Inc. stock logo
XBIT
XBiotech
$4.01M24.07N/AN/A$5.98 per share0.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$38.53M-$1.29N/AN/AN/A-21.14%-19.55%8/11/2025 (Estimated)

Latest NLTX, ORGO, FLXN, and XBIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.36N/A-$0.36N/AN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
29.15
29.15

Institutional Ownership

CompanyInstitutional Ownership
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
90.01%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
9.13%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
XBiotech Inc. stock logo
XBIT
XBiotech
33.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million20.40 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Flexion Therapeutics stock logo

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$19.75 +0.56 (+2.92%)
As of 07/2/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.35 +0.30 (+7.41%)
Closing price 03:40 PM Eastern
Extended Trading
$4.20 -0.15 (-3.33%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$3.16 -0.06 (-1.71%)
As of 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.